CorMedix Inc.
corporate_fare Company Profile
CorMedix Inc. (NASDAQ:CRMD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CRMD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for CRMD spans 4, 10-Q, 8-K.
Recent high-impact activity:
- CEO Joseph Todisco Buys 80,000 CRMD Shares for $391,200 on the Open Market
- CorMedix 10-Q: Material Weakness Persists as DefenCath Revenue Falls to $17.2M
- CorMedix Q3 Revenue $54.5M Beats Consensus; Suspends 2027 DefenCath Guidance on CMS Changes
- CorMedix Beats Q3 Revenue Estimates but Suspends 2027 DefenCath Guidance
- CorMedix Pays $145M Cash Plus Stock for Heron Assets, Adds Four Commercial Drugs
Financial Snapshot
Short Interest & Short Volume
8.44 days to coverFINRA reported short interest of 14,205,973 shares in CRMD as of the October 30, 2026 settlement, a 3.1% decrease from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 65.4% of CRMD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.